Introduction to
Mutation-Positive FFPE Tumor Blocks
Buy FFPE Mutation-Positive Tumor Blocks for Research
FFPE mutation-positive tumour blocks provide preserved cancer tissue containing one or more documented genomic alterations. Researchers may request tumours with mutations in genes such as EGFR, KRAS, NRAS, BRAF, PIK3CA, TP53, BRCA1 or BRCA2, depending on the disease indication and study objective. These blocks can support assay development, drug discovery, biomarker validation, positive-control creation and precision-oncology research. The mutation should be supported by a molecular report identifying the assay, nucleotide and protein change, transcript, variant allele frequency and classification where available.
Researchers should specify whether pathogenic and likely pathogenic variants are acceptable and whether variants of uncertain significance must be excluded. Pathology review should confirm tumour diagnosis, tumour percentage, necrosis and remaining tissue. It is also important to determine whether testing was performed on the supplied block or another specimen from the same patient. Properly documented mutation-positive FFPE blocks can reduce prescreening requirements and support focused molecular research cohorts.
FFPE Mutation -Positive Tumor Blocks With Genomic Data
FFPE mutation-positive tumour blocks with genomic data provide physical tissue linked to detailed molecular findings. In addition to the target mutation, the data may include co-occurring variants, copy-number changes, gene fusions and genomic signatures, depending on the profiling method. This broader information can help researchers investigate molecular pathways, resistance mechanisms and the biological context of a selected alteration. The remaining tissue may be used for IHC, FISH, PCR, repeat sequencing, spatial profiling or digital pathology analysis.
Optimized for DNA Sequencing
NGS-Ready FFPE Tissue Blocks
Reliable RNA Profiling Samples
Source Clinically Annotated Mutation-Positive FFPE Samples
Clinically annotated mutation-positive FFPE samples can be sourced according to molecular alteration, cancer type, stage, treatment exposure and available outcomes. Clinical annotations may include age, sex, diagnosis, histological subtype, specimen site, therapies administered, response, progression and follow-up. Researchers should define mandatory fields before sourcing because many archival cohorts contain pathology and mutation data but limited longitudinal information. Molecular eligibility should be supported by a report identifying the assay, variant, transcript, allele frequency and clinical or biological classification
Clinically Annotated Tissue Samples
FFPE blocks supplied with relevant clinical details for reliable genomic research.
Comprehensive Pathology Data Included
Each sample includes diagnosis, grade, stage, tumor content, and pathology information.
Optimized for Genomic Analysis
Samples are suitable for DNA, RNA, NGS, mutation analysis, and molecular profiling.
Reliable Samples for NGS
Quality-controlled FFPE blocks support accurate sequencing and reproducible genomic results.
FFPE Mutation-Positive Tumor Blocks for Biomarker Validation
FFPE mutation-positive tumour blocks can support biomarker validation by providing tissue with a documented molecular reference. Researchers may use these blocks to assess whether an IHC antibody, PCR assay, FISH probe, sequencing panel or digital pathology model accurately identifies tumours carrying the target alteration. A suitable study should include mutation-positive cases, adequately tested negative cases and relevant disease controls. The reference sequencing method should have appropriate coverage, analytical sensitivity and quality metrics. Researchers should also consider variant type and allele frequency because different alterations within the same gene may not produce identical biological effects.
Â
Pathology review can verify tumour content and identify representative regions for testing. Discordant results may require repeat analysis or orthogonal confirmation. Block age, fixation and tissue depletion should also be considered. Carefully selected mutation-positive FFPE tumour blocks can strengthen analytical evaluation, although larger independent cohorts are required before making conclusions about clinical performance.
Quality-Controlled FFPE Blocks With Confirmed Mutations
Quality-controlled FFPE blocks with confirmed mutations undergo pathology assessment and molecular-result verification before inclusion in a research cohort. A qualified pathologist can review a recent H&E slide to confirm diagnosis, histological subtype, tumour content, necrosis and usable tissue area. The mutation report should identify the testing method, gene, variant, transcript, allele frequency and available quality metrics. Confirmation may come from repeat sequencing, PCR, digital PCR, Sanger sequencing or another suitable orthogonal method, depending on the study requirements.
Researchers should agree on the evidence standard before procurement. The relationship between the tested material and supplied block should be documented because tumour heterogeneity may affect reproducibility. Additional information may include fixation conditions, block age, stage and treatment history. A structured quality-control process helps reduce the risk of receiving tissue with insufficient tumour, degraded material or an unsupported mutation classification.
Order Genomically Verified Mutation -Positive FFPE Tumor Blocks
Genomically verified mutation-positive FFPE tumour blocks can be ordered according to gene, variant, cancer indication and tissue requirements. Researchers should specify whether eligibility is based on any pathogenic alteration within a gene or a precise nucleotide or protein change. The request should also define acceptable testing platforms, minimum variant allele frequency, tumour percentage, maximum necrosis and required tissue quantity. Before final selection, a de-identified manifest and molecular report can be reviewed to confirm that each block meets the criteria.
Pathology quality control should verify diagnosis and ensure sufficient representative tissue remains. Researchers may request unstained slides, tissue curls, extracted DNA or confirmatory testing in addition to the original block. Where negative controls are required, the relevant genomic region must have been adequately analysed. Clear consent, ethics, data-use and material-transfer documentation should accompany the cohort. Custom ordering enables development of precisely defined mutation-positive collections for oncology research and assay validation.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.